ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,215Medicare Part D Prescriptions Filled, Including Refills

Rank: 38 out of 559

$495K Total Retail Price of All Prescriptions

Rank: 32 out of 559

371 Patients Receiving at Least One Drug in Part D
54%Patients 65 Years and Older
67% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New Mexico
Lower avg

Schedule Two
Controlled Substances

22% of this provider’s 371 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

20% of this provider’s 371 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

1% of this provider’s 4,509 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

17% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$54 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

25 is the average number of prescriptions (including refills) per patient, compared to an average of 14.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New Mexico
LISINOPRIL 353 198 1 1
HYDROCODONE-ACETAMINOPHEN 340 118 S3 2 7
GABAPENTIN 324 156 3 9
METFORMIN HCL 312 201 4 5
LEVOTHYROXINE SODIUM 259 182 5 2
OMEPRAZOLE 259 150 5 4
LISINOPRIL-HYDROCHLOROTHIAZIDE 256 181 7 18
OXYCODONE HCL 238 27 S2 8 32
LOVASTATIN 237 174 9 10
SIMVASTATIN 218 146 10 3
AMLODIPINE BESYLATE 201 140 11 6
IBUPROFEN 184 74 12 30
METOPROLOL TARTRATE 166 100 13 12
TRAZODONE HCL 155 49 14 28
HYDROCHLOROTHIAZIDE 151 93 15 8
PROAIR HFA 148 66 16 29
OXYCODONE HCL-ACETAMINOPHEN 148 43 S2 16 70
OXYCONTIN 141 38 S2 18 122
FUROSEMIDE 141 78 18 11
TRAMADOL HCL 121 66 20 27
ZOLPIDEM TARTRATE 119 39 21 17
MELOXICAM 114 63 22 42
FENTANYL 112 0 S2 23 88
FLUTICASONE PROPIONATE 98 56 24 22
ADVAIR DISKUS 93 26 25 46
ATENOLOL 90 53 26 15
CITALOPRAM HBR 87 29 27 21
CARISOPRODOL 78 0 R 28 73
PAROXETINE HCL 75 38 29 48
POTASSIUM CHLORIDE 75 47 29 23
CLONIDINE HCL 69 45 31 68
AMITRIPTYLINE HCL 68 0 R 32 58
FLUOXETINE HCL 67 33 33 37
DOXYCYCLINE HYCLATE 67 23 33 102
CEPHALEXIN 65 30 35 80
PROMETHAZINE HCL 64 0 R 36 116
FLOVENT HFA 60 16 37 129
BUPROPION HCL SR 60 31 37 114
RANITIDINE HCL 59 17 39 26
ALLOPURINOL 58 33 40 34
METHOCARBAMOL 56 0 R 41 144
TERAZOSIN HCL 53 50 42 82
METOPROLOL SUCCINATE 53 40 42 16
LANTUS 52 26 44 40
QUETIAPINE FUMARATE 52 0 44 135
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 9, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.